620 results match your criteria Current problems in cardiology[Journal]


Foreword.

Authors:

Curr Probl Cardiol 2018 Dec;43(12):444

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2018.10.001DOI Listing
December 2018

Aging, MicroRNAs, and Heart Failure.

Curr Probl Cardiol 2018 Dec 29. Epub 2018 Dec 29.

Aging is a major risk factor for heart failure, one of the leading causes of death in Western society. The mechanisms that underlie the different forms of heart failure have been elucidated only in part and the role of noncoding RNAs is still poorly characterized. Specifically, microRNAs (miRNAs), a class of small noncoding RNAs that can modulate gene expression at the posttranscriptional level in all cells, including myocardial and vascular cells, have been shown to play a role in heart failure with reduced ejection fraction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2018.12.003DOI Listing
December 2018
1 Read

Foreword.

Authors:

Curr Probl Cardiol 2019 Apr;44(4):114

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2019.01.001DOI Listing

Modern Management of ST-Segment Elevation Myocardial Infarction.

Curr Probl Cardiol 2018 Sep 14. Epub 2018 Sep 14.

Disruption of intracoronary plaque with thrombus formation resulting in severe or total occlusion of the culprit coronary artery provides the pathophysiologic foundation for ST-segment elevation myocardial infarction (STEMI). Management of STEMI focuses on timely restoration of coronary blood flow along with antithrombotic therapies and secondary prevention strategies. The purpose of this review is to discuss the epidemiology, pathophysiology, and diagnosis of STEMI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2018.08.005DOI Listing
September 2018
1 Read

Foreword.

Authors:

Curr Probl Cardiol 2019 Mar;44(3):90

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2018.12.001DOI Listing
March 2019
1 Read

Foreword.

Authors:

Curr Probl Cardiol 2019 Feb;44(2):44

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2018.11.003DOI Listing
February 2019
1 Read

The Medical and Endovascular Treatment of PAD: A Review of the Guidelines and Pivotal Clinical Trials.

Curr Probl Cardiol 2018 Nov 30. Epub 2018 Nov 30.

Peripheral arterial disease (PAD) is a global health problem. The risk factors for developing PAD have been clearly described in the literature, as have the medical therapies and preventative strategies for the prevention and treatment of PAD. Unfortunately, PAD patients remain undertreated with regard to guideline-directed medical therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2018.09.004DOI Listing
November 2018
1 Read

Increasing Diversity in Clinical Trials: Overcoming Critical Barriers.

Curr Probl Cardiol 2018 Nov 9. Epub 2018 Nov 9.

Clinical trial results provide the critical evidence base for evaluating the safety and efficacy of new medicines and medical products. Efficacy and safety may differ among population subgroups depending on intrinsic/extrinsic factors, including sex, age, race, ethnicity, lifestyle, and genetic background. Racial and ethnic minorities continue to be underrepresented in cardiovascular and other clinical trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2018.11.002DOI Listing
November 2018
1 Read

Significance of Pulmonary Hypertension in Hypertrophic Cardiomyopathy.

Curr Probl Cardiol 2018 Oct 17. Epub 2018 Oct 17.

Hypertrophic cardiomyopathy (HCM) is the most prevalent hereditary cardiac disease characterized by the presence of left ventricular and/or septal hypertrophy in the absence of other underlying cardiac disorders. Patients of HCM have a broad range of clinical presentation from being asymptomatic to severely ill condition requires hospitalization and urgent management. Broadly, HCM is classified in two variants: obstructive and nonobstructive. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01462806183015
Publisher Site
http://dx.doi.org/10.1016/j.cpcardiol.2018.10.002DOI Listing
October 2018
11 Reads
3.000 Impact Factor

The Role of Microbiota in Cardiovascular Risk: Focus on Trimethylamine Oxide.

Curr Probl Cardiol 2018 Jul 7. Epub 2018 Jul 7.

The extensive collection of bacteria cohabiting within the host collaborates with human functions and metabolisms in both health and disease. The fine equilibrium of commensals is tightly controlled and an imbalance ("dysbiosis") in the gut microbiota can play different roles in human disease. The development of new genome sequencing techniques has allowed a better understanding of the role of human gut microbiota. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2018.06.005DOI Listing
July 2018
8 Reads

Foreword.

Authors:

Curr Probl Cardiol 2019 Jan;44(1)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2018.11.001DOI Listing
January 2019
2 Reads

Misunderstood or Mistrusted? The Under-Utilization of the Wearable Cardioverter Defibrillator in Clinical Practice.

Curr Probl Cardiol 2018 Sep 18. Epub 2018 Sep 18.

Annually in the United States, sudden cardiac death (including out-of-hospital cardiac arrests) is responsible for over 300,000 deaths, comprising 40%-50% of total mortality rates from cardiovascular disease. Among the highest-risk patients are those with ischemic and nonischemic cardiomyopathy who have a reduced left ventricular ejection fraction (≤ 35%-40%). However, not everyone is a candidate for an implantable cardioverter defibrillator. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2018.09.002DOI Listing
September 2018
2 Reads

Gender Identity, Hormone Therapy, and Cardiovascular Disease Risk.

Curr Probl Cardiol 2018 Sep 20. Epub 2018 Sep 20.

Transgender individuals represent a medically underserved and under researched population. There is a growing number of studies illustrating the importance of hormone therapy treatments in transgender men and women to assist ameliorating gender dysphoria and promoting well-being. However, the cardiovascular effects of these hormones are controversial. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01462806183014
Publisher Site
http://dx.doi.org/10.1016/j.cpcardiol.2018.09.003DOI Listing
September 2018
16 Reads

Impact of Nutrition on CardiovascularFunction.

Curr Probl Cardiol 2018 Sep 11. Epub 2018 Sep 11.

The metabolic sources of energy for myocardial contractility include mainly free fatty acids (FFA) for 95%, and in lesser amounts for 5% from glucose and minimal contributions from other substrates such lactate, ketones, and amino acids. However, myocardial efficiency is influenced by metabolic condition, overload, and ischemia. During cardiac stress, cardiomyocytes increase glucose oxidation and reduce FFA oxidation. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01462806183011
Publisher Site
http://dx.doi.org/10.1016/j.cpcardiol.2018.08.003DOI Listing
September 2018
3 Reads

Foreword.

Authors:

Curr Probl Cardiol 2018 Nov;43(11):420

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2018.09.001DOI Listing
November 2018
2 Reads

Outcomes of Percutaneous Antegrade Intraluminal Coronary Intervention of Chronic Total Occlusion With Remote Surgical Backup.

Curr Probl Cardiol 2018 Aug 22. Epub 2018 Aug 22.

Percutaneous coronary intervention (PCI) of chronic total occlusion (CTO) is not favored in facilities without on-site surgical backup. We reviewed outcomes of patients who had CTO intervention with remote surgical backup in our institution. All patients who underwent attempted antegrade intraluminal CTO PCI from January 2013 to July 2017 were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2018.08.002DOI Listing
August 2018
2 Reads

Foreword.

Authors:

Curr Probl Cardiol 2018 Oct;43(10):396

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2018.08.001DOI Listing
October 2018
1 Read

Foreword.

Authors:

Curr Probl Cardiol 2018 Sep;43(9):362

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2018.07.002DOI Listing
September 2018
1 Read

SGLT-2 Inhibitors and Peripheral Artery Disease: A Statistical Hoax or Reality?

Curr Probl Cardiol 2018 Jul 6. Epub 2018 Jul 6.

Inhibitors of sodium-glucose cotransporters type-2 are the most recent addition to the armamentarium of oral antidiabetic agents. This class of drugs has shown promising results in glycemic control and most importantly to reduce cardiovascular disease (CVD) mortality risk. Despite the encouraging data, there is concern regarding their potential for causing or worsening peripheral artery disease (PAD), which may increase the risk of lower extremity amputations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2018.06.004DOI Listing
July 2018
3 Reads
3.000 Impact Factor

Atrial Fibrillation and Deterioration in Cognitive Function.

Curr Probl Cardiol 2018 Jul 11. Epub 2018 Jul 11.

The link between atrial fibrillation and cognitive decline and dementia has gained interest of the medical community lately. More research is being conducted to prevent and or delay this morbidity as no curative therapy is available for cognitive decline and dementia. The exact mechanism of causation is unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2018.07.001DOI Listing
July 2018
3 Reads

Empowering the Aging with Mobile Health: A mHealth Framework for Supporting Sustainable Healthy Lifestyle Behavior.

Curr Probl Cardiol 2018 Jul 9. Epub 2018 Jul 9.

Healthcare providers are shifting to a value-based model that acknowledges the importance of a healthy lifestyle for managing chronic disease and mental health. This approach empowers patients to adopt and/or sustain healthy lifestyle choices through the use of innovative technologies-providing beneficial ways of delivering health literacy, self-monitoring, and patient-provider collaboration. Such pathways have the potential to enable healthy lifestyle management for a growing U. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2018.06.003DOI Listing
July 2018
3 Reads

Risk Reduction to Disease Management: Clinical Pharmacists as Cardiovascular Care Providers.

Curr Probl Cardiol 2018 Aug 4. Epub 2018 Aug 4.

Most cardiovascular diseases are caused by modifiable risk factors yet prevalence continues to increase and heart disease remains the leading cause of death in the United States. Screening, identifying and appropriately managing high risk patients are strategies to shift the paradigm from treatment to prevention. Pharmacists are an underutilized population health resource despite robust evidence to support their roles as interdisciplinary team members and direct patient care providers in both inpatient and outpatient settings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2018.07.003DOI Listing
August 2018
2 Reads

Ultrasonography in Heart Failure: A Story that Matters.

Curr Probl Cardiol 2019 Apr 21;44(4):116-136. Epub 2018 Jun 21.

Heart failure (HF) is a clinical syndrome caused by structural and/or functional cardiac abnormalities, resulting in a reduced cardiac output and/or elevated intracardiac pressures at rest or during stress. It is the leading cause of hospitalization in Internal Medicine departments. This article aims at reviewing evidence of the importance of ultrasound in HF both for hospitalized patients and in the follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2018.05.003DOI Listing
April 2019
11 Reads

Applying Precision Medicine to Healthy Living for the Prevention and Treatment of Cardiovascular Disease.

Curr Probl Cardiol 2018 Dec 14;43(12):448-483. Epub 2018 Jun 14.

Healthy living medicine (HLM) is an emerging concept that recognizes the importance of: (1) Moving more and sitting less; (2) Consuming a healthy diet at the appropriate caloric load; (3) Maintaining a healthy body weight; and (4) Not smoking. Suffice to say, HLM should be practiced by all health professionals, prescribing a personalized healthy living polypill to individuals under their care while titrating the dosage for optimal adherence and therapeutic efficacy. Traditionally, HLM, particularly when practiced in the context of physical activity and diet, is commonly viewed as an all-or-none and one-size-fits-all paradigm. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01462806183008
Publisher Site
http://dx.doi.org/10.1016/j.cpcardiol.2018.06.001DOI Listing
December 2018
9 Reads

Foreword.

Authors:

Curr Probl Cardiol 2018 Aug;43(8):312

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2018.06.002DOI Listing
August 2018
2 Reads

Long QT Syndrome: A Comprehensive Review of the Literature and Current Evidence.

Curr Probl Cardiol 2019 Mar 10;44(3):92-106. Epub 2018 May 10.

Long QT syndrome (LQT) represents a heterogeneous family of cardiac electrophysiologic disorders characterized by QT prolongation and T-wave abnormalities on the electrocardiogram. It is commonly associated with syncope, however, sudden cardiac death can occur due to torsades de pointes. LQT is a clinical diagnosis and should be suspected in individuals on the basis of clinical presentation, family history and ECG characteristics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2018.04.002DOI Listing
March 2019
6 Reads

Current Evidence-Based Understanding of the Epidemiology, Prevention, and Treatment of Atrial Fibrillation.

Curr Probl Cardiol 2018 Jun 7;43(6):241-283. Epub 2017 Jun 7.

Atrial fibrillation (AF) is the most common atrial arrhythmia in adults worldwide. As medical advancements continue to contribute to an ever-increasing aging population, the burden of atrial fibrillation on the modern health care system continues to increase. Therapies are also evolving, for treatment of the arrhythmia itself, and stroke risk mitigation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2017.06.001DOI Listing
June 2018
3 Reads

Degenerative Mitral Stenosis: From Pathophysiology to Challenging Interventional Treatment.

Curr Probl Cardiol 2019 Jan 6;44(1):10-35. Epub 2018 Apr 6.

Mitral stenosis (MS) is characterized by obstruction of left ventricular inflow as a result of narrowing of the mitral valve orifice. Although its prevalence has declined over the last decade, especially in developed countries, it remains an important cause of morbidity and mortality.  The most often cause of MS worldwide is still postrheumatic mitral valve disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2018.03.004DOI Listing
January 2019
4 Reads

Enhancing Participation in Cardiac Rehabilitation: A Question of Proximity and Integration of Outpatient Services.

Curr Probl Cardiol 2018 Nov 6;43(11):424-435. Epub 2018 Mar 6.

Numerous investigations have established the strong clinical utility of cardiac rehabilitation, while clinical guidelines continually call for a high level of referral and participation. Historically, medical facilities have faced challenges referring eligible patients to cardiac rehabilitation, enrolling only a small portion of those receiving referral. Consequently, less than ~10% of qualifying patients receive any amount of cardiac rehabilitation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2018.02.002DOI Listing
November 2018
10 Reads

Foreword.

Authors:

Curr Probl Cardiol 2018 May;43(5):188

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2018.03.001DOI Listing
May 2018
4 Reads

Let Us Talk About Moving: Reframing the Exercise and Physical Activity Discussion.

Curr Probl Cardiol 2018 Apr 7;43(4):154-179. Epub 2017 Jun 7.

Noncommunicable and chronic disease are interchangeable terms. According to the World Health Organization, "they are of long duration and generally slow progression. The 4 main types of chronic diseases are cardiovascular diseases (ie, heart attacks and stroke), cancers, chronic respiratory diseases (such as chronic obstructive pulmonary disease and asthma), and diabetes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2017.06.002DOI Listing
April 2018
8 Reads

Assessing the Value of Moving More-The Integral Role of Qualified Health Professionals.

Curr Probl Cardiol 2018 Apr 11;43(4):138-153. Epub 2017 Jul 11.

School of Health Sciences, Faculty of Health, University of Tasmania, Launceston, TAS, Australia.

Being physically active or, in a broader sense, simply moving more throughout each day is one of the most important components of an individual's health plan. In conjunction with regular exercise training, taking more steps in a day and sitting less are also important components of one's movement portfolio. Given this priority, health care professionals must develop enhanced skills for prescribing and guiding individualized movement programs for all their patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2017.07.001DOI Listing
April 2018
8 Reads

Foreword.

Authors:

Curr Probl Cardiol 2018 Apr;43(4):134

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2018.02.001DOI Listing
April 2018
4 Reads

Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus.

Curr Probl Cardiol 2018 Mar 10;43(3):68-110. Epub 2017 May 10.

Diabetes mellitus (DM) has become a public health problem worldwide, and it has large implications for cardiovascular disease (CVD). In this article, we discuss the etiology and pathophysiology of CVD in DM including the effects of abnormal glucose homeostasis, genetic factors, epigenetics, apoptosis, common pathophysiological mechanisms shared by both DM and CVD, and contributions of other comorbidities. We then cover the pathogenesis of both atherosclerotic disease and cardiomyopathy in relation to DM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2017.05.001DOI Listing
March 2018
5 Reads

Foreword.

Authors:

Curr Probl Cardiol 2018 Mar 3;43(3):65. Epub 2018 Jan 3.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2018.01.001DOI Listing
March 2018
4 Reads

Accurate Prediction of False ST-Segment Elevation Myocardial Infarction: Ready for Prime Time?

Curr Probl Cardiol 2018 Oct 3;43(10):400-412. Epub 2018 Jan 3.

The incidence of inappropriate cardiac catheterization lab activation for treatment of a false ST-segment elevation myocardial infarction (STEMI) has been reported to be 2.6%-36%. Excessive inappropriate catheterization lab activation may be associated with risks to patients, provider fatigue and improper resource usage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2017.12.003DOI Listing
October 2018
6 Reads

Neurohormonal Imbalance: A Neglected Problem-And Potential Therapeutic Target-In Acute Heart Failure.

Curr Probl Cardiol 2018 Jul 16;43(7):294-304. Epub 2017 Dec 16.

Decompensated or acute heart failure (AHF) is characterized by increased ventricular and atrial pressures which may lead to and be caused by circulatory congestion. Unless due to a primary decrease in cardiac function, congestion arises from volume expansion or vasoconstriction. In turn, volume expansion and vasoconstriction are due to neurohormonal imbalance since both result from activation of the sympathetic nervous system, the renin-angiotensin-aldosterone axis and excess secretion of arginine vasopressin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2017.12.002DOI Listing
July 2018
12 Reads

Treatment Strategies in Symptomatic Intermediate, Low-Risk, and Asymptomatic Patients With Severe Aortic Stenosis.

Curr Probl Cardiol 2018 Aug 12;43(8):335-354. Epub 2017 Dec 12.

Survival of symptomatic patients with severe aortic stenosis (AS) is very poor, with an average mortality reaching up to 2% per month. Approach to diagnosis and treatment of patients with AS was conservative; patients were referred to surgery only if the AS-induced symptoms become apparent and significantly limit the quality of patient' life. In the past 15 years, the novel treatment strategy in subgroups of symptomatic patients with AS have been the subject of extensive research, starting from introduction of transcatheter aortic valve implant (TAVI) in inoperable symptomatic patients with severe AS and continuing further to patients with very high and high operative risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2017.12.001DOI Listing
August 2018
6 Reads

Wearable Cardioverter Defibrillator "The Lifevest": Device Design, Limitations, and Areas of Improvement.

Curr Probl Cardiol 2018 Feb 15;43(2):45-55. Epub 2017 Apr 15.

Sudden cardiac death is a potentially fatal clinical event demanding use of emergent intervention such as defibrillation. Over the last 1 decade, development of devices such as implantable and wearable cardioverter defibrillators (WCD) has provided new avenues in the management of sudden cardiac death. Several clinical studies have commented on the therapeutic and preventive aspect of WCD, however, literature describing the device functioning and limitations is limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2017.04.002DOI Listing
February 2018
39 Reads
1 Citation
3.000 Impact Factor

Foreword.

Authors:

Curr Probl Cardiol 2018 Feb;43(2):42

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2017.11.001DOI Listing
February 2018
6 Reads

Aortic Valve Regurgitation: A Comprehensive Review.

Curr Probl Cardiol 2018 Aug 2;43(8):315-334. Epub 2017 Nov 2.

Aortic regurgitation (AR) has an estimated prevalence of 4.9% in the Framingham study, with moderate or severe AR occurring in 0.5% of the study population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2017.10.004DOI Listing
August 2018
9 Reads

Current Trends and Future Perspectives in the Treatment of Pulmonary Arterial Hypertension.

Curr Probl Cardiol 2018 May 31;43(5):191-216. Epub 2017 Oct 31.

Department of Medicine, Division of Cardiology, East Tennessee State University, Johnson City, TN, USA. Electronic address:

Pulmonary hypertension continues to be a life-threatening illness with debilitating physical and emotional consequences affecting around 1% of global population. The progression of this devastating disease is characterized by increase in pulmonary vascular resistance resulting in elevated pulmonary pressure, eventually leading to right heart failure and death. Better understanding of pathophysiology has led to substantial improvements in terms of availability of treatment options. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2017.10.002DOI Listing
May 2018
6 Reads
3.000 Impact Factor

Cardiac Amyloidosis: An Updated Review With Emphasis on Diagnosis and Future Directions.

Curr Probl Cardiol 2018 Jan 13;43(1):10-34. Epub 2017 Apr 13.

Cardiac amyloidosis occurs because of abnormal protein (amyloid) deposition in the cardiac tissue. Even with advanced diagnostic techniques and treatments, the prognosis of amyloidosis remains poor. The diagnosis of cardiac amyloidosis particularly needs to be in the differential in patients presenting with heart failure with preserved ejection fraction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2017.04.003DOI Listing
January 2018
13 Reads
3.000 Impact Factor

Current Trends and Future Perspectives in the Treatment of Pulmonary Hypertension: WHO Group II-V.

Curr Probl Cardiol 2018 May 31;43(5):217-231. Epub 2017 Oct 31.

Pulmonary hypertension continues to be a life-threatening illness with debilitating physical and emotional consequences affecting around 1% of global population. The progression of this devastating disease is characterized by increase in pulmonary vascular resistance resulting in elevated pulmonary pressure, eventually leading to right heart failure and death. Better understanding of pathophysiology has led to substantial improvements in terms of availability of treatment options. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01462806173015
Publisher Site
http://dx.doi.org/10.1016/j.cpcardiol.2017.10.003DOI Listing
May 2018
16 Reads
3.000 Impact Factor

Foreword.

Authors:

Curr Probl Cardiol 2018 Jan 2;43(1). Epub 2017 Nov 2.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2017.10.001DOI Listing
January 2018
6 Reads

Pregnancy and Heart Disease: Pregnancy-Associated Hypertension and Peripartum Cardiomyopathy.

Curr Probl Cardiol 2018 Sep 31;43(9):364-388. Epub 2017 Oct 31.

Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.

Cardiovascular diseases are major complications in pregnancy worldwide and the number of patients who develop cardiac problems during pregnancy is increasing. Pregnancy-associated hypertensive complications such as pre-eclampsia (PE) or peripartum cardiomyopathy (PPCM) are potentially life-threatening heart diseases emerging during pregnancy, under delivery or in the first postpartal months in previously healthy women. Both disease entities display substantial morbidity and mortality in the acute phase. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2017.10.005DOI Listing
September 2018
7 Reads

Duration of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Curr Probl Cardiol 2017 Dec 16;42(12):404-417. Epub 2017 Apr 16.

Division of Cardiovascular Medicine, State University of New York Downstate Medical Center, New York, NY.

To evaluate the efficacy and safety of long-duration dual antiplatelet therapy (L-DAPT) compared to short-duration dual antiplatelet therapy (S-DAPT) after drug-eluting stent implantation. We searched Medline, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) to identify randomized controlled trials assessing the clinical effect of L-DAPT vs S-DAPT after drug-eluting stent. Efficacy end points were all-cause mortality, cardiac mortality, myocardial infarction (MI), stent thrombosis (ST), and target vessel revascularization (TVR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpcardiol.2017.04.001DOI Listing
December 2017
27 Reads